The early assessment report from horizon scanning is sent to the county councils and the New Therapies Council approximately six months before estimated marketing authorisation. Based on this, the New Therapies Council makes a decision on whether the medicine should be subject to national managed introduction.
The county councils are able to submit their opinion to the New Therapies Council on whether the new medicine should be subject to joint introduction. The New Therapies Council decision is guided by a check list of the same criteria as used in the horizon scanning process.
Not all new medicines are described in early assessment reports from Horizon scanning. However, the county councils have the possibility of nominating any medicine to the New Therapies Council for inclusion in the national managed introduction process.